Cytek Biosciences (CTKB) Income from Non-Controlling Interests (2021 - 2023)

Cytek Biosciences has reported Income from Non-Controlling Interests for 3 years, with the latest figure at -$235000.0 in Q1 2023.

• For the quarter ending Q1 2023, Income from Non-Controlling Interests fell 71.53% year-over-year to -$235000.0; the trailing twelve-month figure through Dec 2023 stood at -$46000.0 (down 139.66% YoY), and the FY2022 full-year result was -$92000.0, down 453.85% from the prior year.
• Income from Non-Controlling Interests for Q1 2023 stood at -$235000.0, down from $189000.0 in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $315000.0 in Q1 2021, with the low at -$315000.0 in Q2 2021.
• Historically, Income from Non-Controlling Interests has averaged -$11625.0 across 3 years, with a median of -$7000.0 in 2021.
• The largest YoY upside for Income from Non-Controlling Interests was 626.92% in 2022 against a maximum downside of 143.49% in 2022.
• Cytek Biosciences' Income from Non-Controlling Interests stood at $26000.0 in 2021, then jumped by 626.92% to $189000.0 in 2022, then plunged by 224.34% to -$235000.0 in 2023.
• The last three Income from Non-Controlling Interests figures came in at -$235000.0 (Q1 2023), $189000.0 (Q4 2022), and -$40000.0 (Q3 2022), per Business Quant data.